Drug Database
GA

GamaSTAN (GamaSTAN)

✓ Approved

Grifols, S.A. · 多克隆抗体 · 多克隆抗体

什么是 GamaSTAN?

GamaSTAN 是一种多克隆抗体,由Grifols, S.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名GamaSTAN
公司Grifols, S.A.
药物类别多克隆抗体, 重组蛋白, 抗体
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

GamaSTAN 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeasles✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved
Immune system disordersImmunodeficiency✓ Approved
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026-10-08

Immunoglobulin Use, Availability, and Administration Considerations in Measles Prevention.

Le Dustin D, Ahmed Amina A, Raschka Michael M, Stinchfield Patricia P et al.

In 2026, the National Foundation for Infectious Diseases (NFID), with the Infectious Diseases Society of America (IDSA), convened a Measles Summit in response to the largest U.S. measles resurgence in over three decades, with more than 3,000 confirmed cases mostly among unvaccinated individuals. Many clinicians and public health professionals have limited firsthand measles experience, underscoring the need for clinical guidance. In this commentary, we examine immune globulin (IG) use for measles post-exposure prophylaxis (PEP) amid fragile supply and logistical challenges. GamaSTAN®, the sole Food and Drug Administration (FDA)-licensed intramuscular IG product, faces episodic availability, non-returnable single-vial economics, and a 2013 recommendation to double the PEP dose, increasing per-patient demand. IVIG is increasingly employed when patients weigh 30 kg or more, beyond the weight at which an adequate dose of immune globulin can be given intramuscularly, or when IMIG supply is constrained, while concurrent lot withdrawals compromise institutional formularies. We review evidence-based patient selection for PEP, emphasizing that the Measles, Mumps, and Rubella (MMR) vaccine remains first-line within 72 hours of exposure, with IG reserved when vaccination is contraindicated or potentially ineffective. Immunosuppressive therapies vary widely in their effects on the safety and efficacy of live vaccines. We therefore argue against categorizing every biologic, immunomodulator, or steroid as an automatic MMR contraindication, which would overestimate IG-PEP demand and preclude MMR for eligible patients. We propose class-specific stratification and an electronic health record decision-support rule to better align IG demand with genuine need. Finally, we address declining potency standards for measles antibody, attributable to waning donor titers, and offer guidance on dosing, multi-site pediatric administration, and infusion logistics within the PEP window.

PMID 42847317
阅读全文 →
PubMedMMWR. Morbidity and mortality weekly report2017-09-15

Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.

Nelson Noele P NP

GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella viruses (1). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma (2). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.

PMID 28910270
阅读全文 →
PubMedAmerican journal of hematology2013-08-03

Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.

Menis Mikhail M, Sridhar Gayathri G, Selvam Nandini N, Ovanesov Mikhail V MV et al.

Thrombotic events (TEs) are rare serious complications following administration of hyperimmune globulin (HIG) products. Our retrospective claims-based study assessed occurrence of same-day TEs following administration of HIGs during 2008-2011 and examined potential risk factors using HealthCore's Integrated Research Database (HIRD(SM) ) and laboratory testing of products' procoagulant Factor XIa activity by U.S. Food and Drug Administration. Multivariable regression was used to estimate same-day TE risk for different products. Of 101,956 individuals exposed to 23 different HIG product groups, 86 (0.84 per 1,000 persons) had a TE diagnosis code (DC) recorded on the same day as HIG administration. Unadjusted same-day TE DC rates (per 1,000 persons) ranged from 0.4 to 148.9 for different products. GamaSTAN S/D IG >10 cc had statistically significantly higher same-day TE DC risk compared to Tetanus IG (OR = 57.57; 95% CI = 19.72-168.10). Increased TE risk was also observed with older age (≥45 years), prior thrombotic events, and hypercoagulable state(s). Laboratory investigation identified elevated Factor XIa activity for GamaSTAN S/D, HepaGam B, HyperHep B S/D, WinRho SDF, HyperRHO S/D full dose, and HyperTET S/D. Our study, for the first time, identified increase in the same-day TE DC risk with GamaSTAN S/D IG >10 cc and suggests potentially elevated TE risk with other HIGs.

PMID 23907744
阅读全文 →
PubMedPostgraduate medicine1995-02-01

Kawasaki syndrome. An important consideration in the febrile child.

Applegate B L BL

Many aspects of Kawasaki syndrome remain a mystery. The cause of the disease has eluded researchers, and its pathophysiology is a subject of much debate. However, the diagnostic features have been identified: A significant fever for at least 5 days, bilateral nonexudative conjunctivitis, erythema of the palms and soles, a polymorphic diffuse rash, cervical lymphadenopathy, and injection of the mouth and oropharynx. The recently instituted treatment protocol of high-dose aspirin with gamma globulin (Gamastan, Gammar) helps patients recover more quickly and with fewer potentially life-threatening sequelae than does aspirin alone.

PMID 7855030
阅读全文 →
PubMedPostgraduate medicine1992-02-15

Hepatitis A, B, C, D, and E. Update on testing and treatment.

Kools A M AM

Five major types of viral hepatitis have been identified. Hepatitis A is an acute, usually self-limited illness. Prophylaxis with immune globulin (Gamastan, Gammar) is effective in household and sexual contacts of infected patients. Hepatitis B has both acute and chronic forms. Treatment trials for chronic hepatitis B with interferon alfa-2b have shown promise. Hepatitis C is the name now given to non-A non-B hepatitis. Interferon alfa-2b (Intron A) has been approved for treatment of chronic hepatitis C. Hepatitis D occurs only in patients with hepatitis B. The only treatment for hepatitis D is prevention of hepatitis B. Hepatitis E is seen after natural disasters in developing regions of the world. Further advances in serologic testing and treatment of viral hepatitis can be expected.

PMID 1741356
阅读全文 →
PubMedPostgraduate medicine1988-07-01

Immunoprophylaxis of viral hepatitis.

Bruckstein A H AH

Because safe, effective treatment for established viral hepatitis is not available, physicians need to be acquainted with recent advances in prophylaxis. Immune globulin (Gamastan, Gammar) is used for both preexposure and postexposure prophylaxis of hepatitis A, and side effects are rare. Two vaccines (Heptavax-B, Recombivax HB) are licensed for hepatitis B, one is a plasma-derived vaccine, the other a yeast-recombinant vaccine. Indirectly, these also control hepatitis D (delta agent), which needs hepatitis B virus to develop.

PMID 2968545
阅读全文 →

注册免费账户还可查看另外 3 篇文献

免费注册查看全部文献 →

了解更多GamaSTAN